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ABSTRACT 
 
Heterozygous germ-line mutations of BMPR2 are the major contributor to familial clustering of 
pulmonary arterial hypertension (PAH). To further explore the genetic basis of PAH in isolated 
cases we undertook a candidate gene analysis to identify potentially deleterious variation. 
Members of the BMP pathway, namely SMADs 1, 4, 5 and 9, were screened by direct sequencing 
for gene defects. Four variants were identified in SMADs 1, 4 and 9 amongst a cohort of 324 
PAH cases, each not detected in a in a substantial control population. Of three amino-acid 
substitutions identified, two demonstrated reduced signaling activity in vitro. A putative splice 
site mutation in SMAD4 resulted in moderate transcript loss due to compromised splicing 
efficiency. These results emphasize the central role of BMPR2 mutation in the pathogenesis of 
PAH and indicate that variation within the SMAD family represents an infrequent cause of 
disease. 
 
 
Key Words: pulmonary hypertension • BMPR2 • Receptor SMADs • SMAD4 • transcriptional 
regulation. 
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PAH (MIM# 178600) is a progressive vascular disorder often fatal as a result of right heart 
failure [Humbert et al., 2010]. Mutations of BMPR2 (MIM# 600799), encoding a bone 
morphogenetic type II receptor of the TGF-β family, are the major genetic determinant in familial 
PAH (FPAH). Idiopathic PAH (IPAH), defined as arising spontaneously in the absence of a 
recorded family history of disease, is indistinguishable from the familial form [Machado et al., 
2009]. The detection of germ-line BMPR2 mutation in ~25% of IPAH cases, posing hereditary 
risk to offspring, has led to the re-classification of mutation carriers as heritable PAH (HPAH) 
[Deng et al., 2000; Lane et al., 2000; Machado et al., 2009]. Over 70% of HPAH mutations 
predict premature truncation likely leading to transcript loss via the nonsense-mediated decay 
(NMD) pathway [Machado et al., 2009]. Deleterious BMPR2 mutation in the IPAH population 
indicates a genetic basis to disease and suggests the existence of additional genetic and/or 
environmental factors in PAH pathogenesis yet to be fully annotated. Indeed, rare disease alleles 
of the TGF-β receptors, ALK1 (MIM# 601284) and endoglin (MIM# 131195), and members of 
the SMAD family have recently been shown to underlie susceptibility to HHT and pulmonary 
hypertension [Harrison et al., 2005; Shintani et al., 2009]. BMPR-II triggers signal transduction 
through the receptor SMADs (R-SMADs) 1, 5 and 9, upon ligand binding and complex formation 
with a type I receptor, namely BMPR-1A, -1B or ALK1. R-SMADs translocate to the nucleus in 
complex with co-SMAD4 to regulate transcription of target genes, a process dependent on the 
presence of a conserved proximal DNA binding MH1 domain and a trans-activating MH2 
domain [Massague et al., 2000]. As impaired responses to BMP-specific SMADs are 
acknowledged as critical in the development of PAH [Nishihara et al., 2002; Rudarakanchana et 
al., 2002], we sought to assess the genetic contribution of this pathway to disease susceptibility 
by conducting an extensive survey of a large PAH cohort, excluded for BMPR2 mutation. Here 
we report the identification of four gene defects in SMAD1 (MIM# 601595), SMAD4 (MIM# 
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600993) and SMAD9 (MIM# 603295). Functional analyses suggest significant, albeit limited 
consequences on transcript integrity, signaling and target gene regulation. 
Ethical approval for these studies was obtained by local ethical committees and all patients 
provided informed consent. A diagnosis of PAH was confirmed as described previously 
[Machado et al., 2009]. The European IPAH cohort comprised a total of 158 subjects ascertained 
by specialist UK and European centers and displayed a gender bias favoring females (1.9:1). The 
PAH panel with associated disease (APAH) (n=136) comprised cases with HIV infection (n=9), 
portal hypertension (n=11), congenital heart disease (n=15), thromboembolic disease (n=42) and 
connective tissue disease (n=59). Japanese IPAH subjects (n=30) were ascertained through a 
single specialist referral centre. All patients had been screened for BMPR2 mutation by direct 
sequencing and/or DHPLC employing primer sets previously described [Machado et al., 2001]. 
Direct sequencing was performed on ABI377 fragment analyzer. DHPLC was performed using 
the Transgenomic WAVE Nucleic Acid Fragment Analysis system containing a DNASep 
column (Transgenomic, Crewe, UK) according to manufacturer’s instruction. Due to the inherent 
limitations of these techniques in detecting large genomic rearrangements the existence of 
BMPR2 mutation in a small proportion of samples cannot be categorically excluded. The control 
population, derived from the 1958 British birth cohort and in-house samples were of self-defined 
Western European ancestry (n=960) or of Japanese descent (n=340), ranging between the 3
rd
 and 
5
th
 decade of life. An additional panel of French controls (n=284) were used to further confirm 
absence of variation identified in patients of French origin. All coding exons, intron-exon 
boundaries and splice isoforms of the candidate genes SMAD1, SMAD4, SMAD5 (MIM# 603110) 
and SMAD9 were DNA sequenced and analyzed on an ABI3730xl DNA Analyzer as per standard 
protocols [Southgate et al., 2011]. Wild-type constructs for SMADs 1, 4 and 9 were obtained 
from Addgene. Variation was introduced by performing site-directed mutagenesis with the 
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QuickChange kit (Stratagene) on the wild-type template according to the manufacturer’s 
instructions. Constructs to determine splicing efficiency, splicing and luciferase assays are 
described in Supplementary methods. RNA was isolated from mammalian cells using TRI-
Reagent (Sigma), and cDNA was synthesized using random primers and MMLV Reverse 
Transcriptase (Promega) following the manufacturer’s protocol. RT-PCR was carried out using 
Hi-Fidelity Extensor Master Mix (ABgene). Quantitative PCR for determining transcript levels of 
SMAD4, inhibitor of DNA binding 2 (Id2), beta actin and GAPDH were performed using 
TaqMan Gene Expression Assays (Applied Biosystems) on a 7900HT Fast Real-Time PCR 
system (Applied Biosystems) according to the manufacturer’s protocol. Lung tissue from the 
patient harboring the SMAD9 variant was fixed in 10% buffered formalin and embedded in 
paraffin as per standard procedures. Five-mm-thick sections were serially cut and stained with 
hematoxylin and eosin and Elastica van Gieson for histological examination by light microscopy. 
Several known polymorphisms but no putative mutations were identified in the APAH samples. 
Screening of SMAD1 in the IPAH patient series revealed a novel missense variant (c.8T>C, 
p.V3A) within exon 1, upstream of the MH1 domain (Fig. 1A). Within SMAD4 two defects were 
identified in independent IPAH cases, namely a predicted splice-site mutation (c.1448-6T>C) 
upstream of the terminal exon 11 and a missense variant (c.38A>G, p.N13S) (Fig. 1A-C). A 
novel missense variant, (c.127A>G, p.K43E), was observed in a patient of Japanese origin in 
SMAD9 impacting upon the MH1 domain (Fig. 1A). The lack of parental material precluded a 
determination of whether identified variants were de novo. All variants were absent in 960 
European control samples and an additional 284 French control samples. The SMAD9 variant was 
further excluded from a panel of 340 Japanese controls. Of note, the identified variants were 
absent from the 1000 Genomes database and an in-house repository of 60 exome sequenced 
control samples. All three of the substituted amino acid residues detected in SMADs 1, 4 and 9 
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were highly conserved through evolution, to the level of Takifugu rubripes (Fig. 1D). High 
degrees of conservation have traditionally been considered to be a measure of the potential 
importance of amino acid residues to protein function. The clinical features of the subjects 
harboring potential disease causing variation within SMAD genes are presented in Supp. Table 
S1. To investigate the impact of the missense variants on SMAD mediated signaling, we adapted 
a SMAD reporter assay to be selective to BMP stimulation [Nasim et al., 2008] (Supp. Fig. S1). 
Wild type constructs for SMADs 1 and 4 activated reporter activity as anticipated (Supp. Fig. 
S1). Over-expression of the SMAD1 variant generated reduced basal activity by comparison to 
wild type and impaired responses to ligand stimulation (Fig. 2A and B). The SMAD9 p.K43E 
construct also displayed reduced reporter activity when compared to wild type (Fig. 2C), a 
diminished response to BMPR-II over-expression (Fig. 2C) and stimulation by BMP4 and BMP9 
ligands (Fig. 2D). No difference in the level of activation was seen between the wild type and 
missense SMAD4 constructs either in the absence or presence of ligand (Fig. 2A and data not 
shown) which may indicate subtle effects on function not detectable by this reporter system or the 
possibility that this is an extremely rare population variant with no impact on PAH susceptibility. 
Notably, this impaired activity was modest relative to classical, functionally null BMPR-II 
substitutions underlying familial and hereditary PAH [Nasim et al., 2008]. In silico analysis of 
the c.1448-6T>C variant predicted impaired splicing compared to wild-type [Nalla and Rogan, 
2005]. By quantitative RT-PCR analyses, we observed a putative reduction in transcript level of 
the c.1448-6T>C variant in patient derived leukocytes compared to the wild type; however, due 
to the known variability of mRNA expression in leucocytes this finding was treated as indicative 
(Supp. Fig. 2D). To investigate this observation further we performed RT-PCR on these samples 
and excluded the existence of aberrant splice products thereby indicating pre-mRNA splicing was 
preserved (Supp. Fig. S2A and B) and the NMD surveillance machinery likely not activated 
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although in the absence of a patient cell line formal exclusion of this process could not be 
confirmed. We next questioned whether the reduction in SMAD4 transcript level might be 
explained by an alteration in splicing efficiency. Using an assay of splicing competency (Supp. 
Fig. 2C) [Nasim et al., 2002], we observed a significant reduction in reporter activity for the 
variant construct relative to wild type, consistent with a decrease in splicing efficiency (Fig. 2E). 
Both SMAD4 variants were distinct to mutations observed in HHT alone and JP-HHT, the 
majority of which cluster in the MH2 domain encoded by exons 8-11 [Gallione et al., 2006; Iyer 
et al., 2010]. Unusually, these variants represent the most proximal amino acid substitution and 
only defective splice allele associated with vascular disease but the present data set is insufficient 
to draw meaningful correlations with phenotype. To better elucidate the functional significance of 
SMAD mutations in PAH, we assessed the expression of the Id2 gene in pulmonary artery 
smooth muscle cells (PASMCs) heterozygous for the SMAD9 mutation p.K43E, derived from 
explant lung taken at transplantation which exhibited extensive pulmonary vascular remodeling 
(Supp. Fig S3). The Id2 transcript, a downstream target of BMP and TGF-β signaling was 
significantly reduced in the SMAD9 variant cell line comparative to WT PASMC although 
responses to ligand were largely preserved (Fig. 2F). A similar level of reduction of Id2 transcript 
expression was observed in a PAH cell line with a previously identified, pathogenic BMPR2 
mutation (p.W9X) (Suppl. Fig S4). Western blotting and immunofluorescence revealed no 
differences in protein stability and subcellular localization between WT and missense constructs 
of SMADs 1, 4 and 9 (Supp. Fig S5), suggesting that variant proteins were likely to be present 
and intact in the cell. In light of the moderate effect size of these variants it is plausible that they 
may require one or more genetic or environmental triggers to precipitate disease. Alternatively it 
remains feasible that they may more substantially perturb one or more of the newly emerging 
SMAD-independent pathways. The systematic analysis of the BMP-specific SMAD family in 
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large patient cohorts is of central importance in determining the genetic contribution of this 
pathway, vital in maintenance of the pulmonary vasculature, to the pathogenesis of PAH. The 
low frequency of potentially pathogenic variation in genes encoding SMAD mediators of BMP 
would suggest that SMAD mutation makes a small contribution to inherited genetic susceptibility 
to I/APAH. The application of recent technological advances in high-throughput sequencing of 
coding and whole genomes may prove effective in gaining a fuller understanding of the genetic 
factors contributing to PAH, providing an opportunity for rapid advances in the understanding of 
the molecular mechanisms underlying this disorder. 
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FIGURE LEGENDS 
Figure 1. Identified variation in SMADs 1, 4 and 9. 
A: Sequence chromatograms of the missense defects SMAD1 p.V3A, SMAD4 p.N13S and 
SMAD9 p.K42E, indicating the positions and heterozygous base substitutions relative to wild-
type sequence below. B: Sequence chromatograms displaying the heterozygous splice mutation 
in the terminal intron of SMAD4 (c.1448-6T>C). The horizontal arrows refer to the start of exon 
11 of the gene. Identified mutations in patient samples were numbered at the nucleotide level on 
the basis that +1 corresponded to the A of the ATG translation initiation codon in the reference 
sequence. C: Schematic representation of the genomic organization of SMAD4 and the functional 
domains encoded by the gene, namely the N-terminal MH1 and C-terminal MH2 domains shaded 
in dark grey, separated by the linker region shaded in light grey. Variants identified in this study 
are indicated below the gene structure. Mutations detected in patients with juvenile polyposis 
syndrome associated with HHT (JP-HHT) or HHT alone are depicted by the filled symbols where 
squares represent substitutions, asterisks are small deletions and polygons are nonsense 
mutations. D: Homology comparison of human SMAD1, 4 and 9 illustrating a high level of 
amino acid conservation across species to the level of the Pufferfish (Takifugu rubripes). Amino 
acids substituted in the IPAH patient cohort are highlighted in bold. Non-conserved residues are 
shown in italics. The grey shaded boxes depict the DNA binding MH1 domains. 
 
Figure 2. Effect of SMAD substitutions on downstream signaling. 
A: SMAD-mediated signaling measured by the 3GC2-Lux reporter in the presence of plasmids 
encoding WT and variant SMAD1 (n=13) and SMAD4 (n=8). The basal activity of the reporter 
was set as 100. B: Effect of variant SMAD1 on reporter activity was measured in the presence of 
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BMP4 (n=5) and BMP9 (n=8) ligand stimulation. The activity of the reporter with BMP4 and 
BMP9 ligand stimulation is normalized to 100. C: Basal activation of the reporter by WT and 
variant SMAD9 with (n=7) and without stimulation by BMPR-II (n=9). D: Activation of the 
reporter by WT and variant SMAD9 in the presence of BMP4 (n=4) and BMP9 (n=4) ligand 
stimulation. HEK293 and 293T cells were used in experiments outlined in panels A to B and C to 
D, respectively. An independent plasmid containing the lacZ gene was transfected to normalize 
transfection efficiency. E. The ratio of luciferase and β-galactosidase activities represents mRNA 
splicing efficiency in HEK293 cells (n=12). F. The expression of the Id2 gene was greatly 
reduced in PASMC harboring BMPR2 (p.W9X) (n=4) and SMAD8 (p.K43E) (n=4) variation 
compared to the wild type. G. BMP9 stimulation increased Id2 expression both in wild type 
PASMC (n=4) and in the patient cell line (n=4) although transcript levels in the patient remain 
significantly lower than WT likely due to the lower basal levels of Id2 stimulation. Data represent 
mean ± SD. Data between groups were compared using a paired Student’s t-test. One way 
analysis of variance (ANOVA) followed by Turkey’s HSD tests were carried out for comparison 
of multiple means. A P-value of < 0.05 indicated statistical significance. *P< 0.05  compared with 
corresponding wild types.. 
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Supplementary methods 
 
Generation of constructs, cell culture, transient transfection and enzymatic assay 
To determine splicing efficiency, constructs were developed based on pTN23 which contains a 
recombinant splicing unit flanked by two reporter genes encoding luciferase and β-galactosidase 
proteins [Nasim et al., 2002]. The original splicing unit was further modified by replacing the 
exon SK (pTN23) by exon 11 (120 bp) along with the preceding 40 bp intron of SMAD4 using 
PCR mutagenesis and the resulting fragment was subcloned into SalI/XhoI and BamHI sites of 
pBPLUGA. All plasmids were verified by restriction analyses and sequencing. Cell culture and 
transfections were performed as previously described [Nasim et al., 2008]. Luciferase and β-
galactosidase activities were determined using Dual-light Reporter Assay systems (Applied 
Biosystems) using an ORION-II Plate Luminometer (Berthold) according to manufacturers’ 
protocols. The splicing assay in mammalian cells was performed as previously described [Nasim 
et al., 2002]. 
 
Immunoblotting 
Immunoblotting experiments were conducted on HeLa cells transiently transfected with Flag-
tagged constructs expressing wild-type and missense variant versions of SMAD1, 4 and 8 in 10 
cm dishes. Cells were lysed in 1 ml lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM 
CaCl2, 1% Nonidet P-40, 5 mM EDTA and protease inhibitor cocktail). Proteins were transferred 
onto nitrocellulose and membranes were probed anti-Flag antibody (Sigma Aldrich, F7425). 
diluted 1/500 in blocking buffer (5% milk powder, 0.1% Tween-20 in PBS). Secondary 
antibodies were HRP conjugated and diluted according to manufacturer’s instructions. Proteins 
were detected by chemiluminescence using the EZ-ECL kit (GE Healthcare). 
 
Scanning laser confocal microscopy 
Cells were plated on acid treated coverslips in 6-well plates. Following transfection, cells fixed 
and permeabilised with absolute methanol for 10 min at -20 °C. PBS/1%BSA for 1 h was used as 
a blocking agent after which cells were stained with anti-Flag antibody diluted according to 
manufacturer’s instructions. Anti-mouse Alexa 488 and was employed as the secondary 
antibody. Before examination, coverslips were mounted with Vectashield containing DAPI 
(Vector labs) to facilitate nuclear staining. Confocal microscopy was performed on a Zeiss 
LSM510 laser scanning microscope (Zeiss, Thornwood, NY) using a Zeiss 63 × 1.4 numerical 
aperture oil immersion lens. 
 
Supplementary Figures 
 
 
 
Supplementary Figure 2. RT-PCR on patient leucocytes harbouring the intronic variant c.1448-
6T>C. A. Patient derived cDNA was amplified using two primer sets, positioned in exon 9 and 
11 as indicated in the schematic. The position of the variant is marked. B. Panels FR1 and FR2 
indicate equivalently sized PCR products between WT and mutant samples (mutant reactions in 
duplicate). GAPDH, in the bottom panel, was employed as a loading control. C. Schematic 
representation of the construct employed to determine splicing efficiency. D. The relative level 
of SMAD4 transcript in circulating leukocytes is reduced in a subject harboring c.1448-6T>C 
compared to wild type (WT) as determined by quantitative PCR analysis. The p values as 
calculated by paired student’s t-test are indicated. 
 
 
 
 
 Supplementary Figure 3. Histopathology of pulmonary vascular lesions in the patient with 
SMAD8 substitution stained with Hematoxylin and eosin (H&E) (i, iii and v) and Elastica van 
Gieson (EvG) (ii, iv and vi). (i) and (ii) intra-acinar pulmonary artery (bar=100µm). (iii) and (iv) 
two preacinar arteries (bar=200µm). (v) and (vi) Plexiform lesion (arrowhead) with 
inflammatory infiltrates arising from a stenotic muscular pulmonary artery (bar=200µm). The 
destroyed arterial wall and surrounding thin-walled vessels and the dilatation lesions are 
indicated by arrows and asterisks, respectively.  
 
Supplementary Figure 4. Immunofluorescence and immunoblotting of transiently transfected 
Flag-tagged WT and variant constructs for each observed amino acid substitution. Confocal 
microscopy indicates a cytoplasmic distribution with no evidence of mislocalisation or protein 
degradation in the variants. Western blots indicate the stability of variant proteins is preserved 
for each variant comparative to WT. β-actin was used as a loading control in each experiment. 
 
 
 
Supplementary Table 1. 
 
Table 1. Table of patients’ clinical characteristics 
 Case 1 Case 2 Case 3 Case 4 
SMAD mutations SMAD1 SMAD4 SMAD4 SMAD8 
BMPR2 mutations None None None None 
ALK1 mutations None None None None 
DNA mutation c.8T>C c.38A>G c.1448-6T>C c.127A>G 
Amino-acid change p.V3A p.N13S N/A p.K43E 
Country of origin France France France Japan 
Familial history of PAH No No No No 
Clinical features of HHT No No No No 
Gender Female Female Male Female 
Age at PAH diagnosis 47 35 35 7 
NYHA at diagnosis NYHA IV NYHA III NYHA III NYHA IV 
Six-minute walk distance 
(meters) 
75 293 235 Not done 
Mean pulmonary artery 
pressure (mmHg) 
52 62 100 87 
Mean pulmonary artery wedge 
pressure (mmHg) 
12 12 15 6 
Cardiac index (L/min/m2) 1.53  2.30 2.77 2.17 
Pulmonary vascular resistance 
(mmHg/L/min/m2) 
26.1 21.7 30.7 37.3 
Acute vasodilator challenge Negative Negative Negative Not done 
Treatment Intravenous 
epoprostenol 
Combination of 
bosentan and 
tadalafil 
Intravenous 
epoprostenol  
Intravenous 
epoprostenol 
Lung 
transplantation 
Outcome Death Alive Death Alive 
Cause of death Right heart 
failure 
N/A Right heart 
failure 
N/A 
 
Definition of abbreviations: N/A = Not applicable; NYHA = New York Heart Association 
(functional class of disease severity); mmHg = millimeters of mercury; L/min/m2 = Liters per 
minutes per meter squared. Identified mutations in PAH patient samples were numbered at the 
nucleotide level on the basis that +1 corresponded to the A of the ATG translation initiation 
codon in the reference sequence. 
 
